Telomir Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) on June 8, 2026, reporting events occurring on June 3, 2026. The Company is an emerging growth company incorporated in Florida.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation.
- Compensation: The Company will pay $6,000 per month to the new fractional Chief Financial Officer.
Material Changes
The primary material change reported is a leadership transition in the finance function:
- Departure: Alan Weichselbaum ceased serving as Chief Financial Officer effective June 6, 2026. The departure was not due to any disagreement with the Company regarding operations, policies, or practices.
- Appointment: Andriy Mushak was appointed as Fractional Chief Financial Officer, effective June 6, 2026.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, risk factors, or management commentary regarding the Company's business outlook. The appointment of Mr. Mushak is structured as a consulting engagement with LMAM Consulting Group, LLC, rather than a direct employment relationship. Mr. Mushak brings over 20 years of experience in SEC reporting and financial statement audits.
Key Facts for Investor Verification
- Verify the effective date of the CFO transition (June 6, 2026) and the interim status of financial reporting.
- Confirm the terms of the Consulting Agreement with LMAM Consulting Group, LLC, specifically the $6,000 monthly fee.
- Review the background of Andriy Mushak, including his role as a Partner at LMAM and prior experience at Baker Tilly US, LLP.
- Note that the filing does not disclose any financial performance data or strategic changes beyond the personnel appointment.